<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50659">Dronedarone</z:chebi> (<z:chebi fb="0" ids="50659">Multaq</z:chebi>-Sanofi), an analog of <z:chebi fb="0" ids="2663">amiodarone</z:chebi>, was approved by the FDA in 2009 for oral treatment of paroxysmal or persistent (non-permanent) <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> or <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2663">Amiodarone</z:chebi> (Cordarone, and others) is more effective for this indication, but its use is often limited by its adverse effects, including thyroid and pulmonary toxicity </plain></SENT>
</text></document>